Bilcare Limited Stock Price Today (NSE: BI)

Bilcare Limited

97.62+0.06 (+0.06%)
Market Closed

Fundamental Score

...

Bilcare Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Bilcare Limited share price today is 97.62, up +0.06% on NSE/BSE as of 16 September 2026. Bilcare Limited (BI) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of 147.94 (Cr). The 52-week high for BI share price is 111.51 and the 52-week low is 79.20. At a P/E ratio of 26.80x, BI is currently trading below its industry average P/E of 39.78x. The company has a Return on Equity (ROE) of 1.66% and a debt-to-equity ratio of 3.15.

Bilcare Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
111.51
Low
60.75
Volume
1.5L
Change
+58.21%

Bilcare Limited share price chart: 58.21% return over the past month. 52-week high ₹111.51, 52-week low ₹79.20.

Bilcare Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
99.00102.4392.6997.6240.90K (Cr)
93.0097.5691.2597.5629.67K (Cr)
89.9993.6087.7592.9231.24K (Cr)
89.0692.0089.0089.8326.34K (Cr)
92.6194.0091.3191.6632.48K (Cr)
104.90104.9095.6196.111.92L (Cr)
100.64100.64100.60100.642.07L (Cr)
93.5795.8591.5295.8589.59K (Cr)
88.8991.3987.0491.2925.31K (Cr)
87.0091.5085.0087.0446.58K (Cr)

Bilcare Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
90.80104.9085.0097.62+7.51%
69.00111.5152.5790.80+31.59%
63.7972.0057.0058.17-8.81%
70.0070.0054.0062.69-10.44%
66.6074.0060.0562.06-6.82%
52.8064.8052.8060.24+14.09%
58.0062.2750.0052.76-9.03%
64.8570.8957.5158.27-10.15%
80.7080.7763.0167.20-16.73%
83.0087.7975.4079.67-4.01%
108.00108.0076.1585.50-20.83%
84.95116.0081.40104.78+23.34%

Returns & Performance

Poor

Return on Equity (ROE)

1.66%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

5.56%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

5.99%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Bilcare Limited Valuation Check

Excellent

Price to Earnings (P/E)

26.80x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

39.78x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

30.02%

% shares held by company founders/management

Poor

FII Holding

0.04%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Poor

Promoter Pledged %

1.39%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

301.31%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-3.28%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

3.33%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

16.32%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

16.32%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

3.15x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

0.76x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

273.72 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Bilcare Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of BI across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Attractive Valuation (P/E: 26.80 vs Industry: 39.78)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (301.31%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Excellent EPS Growth (16.32% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (16.32% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Strong Cash Generation (₹273.72 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Risk Factors

7 factors identified

Below-Average Return on Equity (1.66%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (5.56%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Limited Growth History (3.33% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Elevated Debt Levels (D/E: 3.15)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Weak Interest Coverage (0.76x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Limited Institutional Interest (FII+DII: 0.04%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Bilcare Limited vs Healthcare Research, Analytics & Technology Peers

Peer Comparison - Healthcare Research, Analytics & Technology

Compare Bilcare Limited with 8 other companies in the same sector

9 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
28.9/100
98
₹147.94
26.8
Average
1.66%
Poor
5.56%
Poor
3.1
Poor
16.32%
Excellent
3.33%
Average
0.00%
35.4/100
384
₹15510.15
69.9
Average
0.00%
Poor
8.43%
Poor
0.0
Excellent
-0.98%
Poor
11.35%
Good
0.30%
57/100
584
₹14051.21
35.0
Average
13.94%
Average
17.29%
Good
0.0
Excellent
23.02%
Excellent
29.44%
Excellent
0.39%
11.4/100
359
₹9465.47
-78.80%
Poor
-78.35%
Poor
0.0
Excellent
-12.00%
Poor
0.00%
63.6/100
623
₹2782.94
34.9
Average
18.55%
Good
23.39%
Excellent
0.0
Excellent
29.35%
Excellent
14.09%
Good
0.35%
31.2/100
16
₹236.55
18.6
Average
42.11%
Excellent
18.49%
Good
0.0
Excellent
15.08%
Excellent
-41.25%
Poor
0.00%
56.9/100
79
₹166.36
45.8
Average
8.00%
Poor
9.96%
Poor
0.1
Excellent
22.72%
Excellent
151.69%
Excellent
0.00%
24.6/100
16
₹23.52
19.5
Average
3.38%
Poor
6.02%
Poor
0.2
Excellent
-6.68%
Poor
-3.19%
Poor
0.00%
23.9/100
20
₹13.94
163.6
Average
0.76%
Poor
1.39%
Poor
1.8
Average
-24.21%
Poor
-28.62%
Poor
0.00%

Bilcare Limited Quarterly Performance

Latest quarterly metrics for BI — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-3.28%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

301.31%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

3.33%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

16.32%

Compounded annual net profit growth over 5 years

Bilcare Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for BI — calculated from daily price history

55RSI 14
Neutral — RSI 55

Momentum is balanced — neither overbought nor oversold.

SMA 50
73
▲ Price above SMA 50 — Short-term bullish
SMA 200
68
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
113K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Bilcare Limited Financial Statements

Annual income statement, balance sheet and cash flow for Bilcare Limited (BI) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Bilcare Limited

Loading latest quarterly results...

About BI (Bilcare Limited)

Bilcare Ltd is a pioneering force at the intersection of healthcare research, analytics, and technology, dedicated to enhancing pharmaceutical integrity and patient safety globally.... The company distinguishes itself through its commitment to developing advanced packaging solutions that transcend traditional protective measures. Bilcare's multifaceted approach encompasses sophisticated research into material science, focusing on crafting innovative films, foils, and laminates specifically engineered to safeguard the efficacy and stability of solid-dose medications. Beyond mere physical protection, Bilcare is intensely invested in developing advanced anti-counterfeiting technologies and track-and-trace systems, empowering manufacturers to combat the pervasive threat of counterfeit drugs and ensure the authenticity of their products from production to patient consumption. Beyond its packaging solutions, Bilcare extends its expertise into the realm of clinical trial support. Bilcare facilitates the smooth execution of clinical studies through comprehensive trial management, tailored supplies, and logistical support. The company leverages cutting-edge data analytics to derive actionable insights from clinical trial data, accelerating the drug development process and improving trial outcomes. By integrating research, advanced data analytics, and innovative technologies, Bilcare plays a vital role in driving efficiency and transparency in clinical research. This holistic approach reinforces its position as a trusted partner for pharmaceutical companies seeking to navigate the complexities of drug development and regulatory compliance. Furthermore, Bilcare aggressively pursues research and development initiatives to push the boundaries of healthcare technology. It's a forward-thinking company aiming to revolutionize healthcare through material science, data, and pharmaceutical integrity. These ventures are fueled by a deep understanding of the evolving healthcare landscape and the escalating challenges faced by pharmaceutical manufacturers and patients. Bilcare invests in exploring new materials, developing advanced data analytics tools, and creating sophisticated track-and-trace technologies. This emphasis on innovation ensures that Bilcare remains at the forefront of the industry, consistently delivering cutting-edge solutions that address emerging needs and advance the frontiers of pharmaceutical integrity and patient safety.

Company Details

Symbol:BI
Industry:Healthcare Research, Analytics & Technology
Sector:Healthcare Research, Analytics & Technology

Key Leadership

Mr. Mohan Harakchand Bhandari
Chief Executive Officer
Ms. Deepa Mathur
Chief Financial Officer
Mr. Sagar R. Baheti
Company Secretary & Compliance Officer

BI Share Price: Frequently Asked Questions

What is the current share price of Bilcare Limited?

Bilcare Limited (BI) trades at ₹97.62 on NSE and BSE. Market cap ₹147.94 (Cr). Educational data only.

What is the P/E ratio of Bilcare Limited?

Bilcare Limited has a P/E of 26.80x vs industry average 39.78x.

What is the Bull Run score for Bilcare Limited?

Bilcare Limited has a Bull Run score of 28.9/100 based on 25+ financial parameters.

Does Bilcare Limited pay dividends?

Bilcare Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Bilcare Limited?

Bilcare Limited has ROE of 1.66%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Bilcare Limited?

Bilcare Limited has debt-to-equity of 3.15.

Is Bilcare Limited a good investment?

Bull Run gives Bilcare Limited a score of 28.9/100. This is not investment advice — consult a SEBI-registered advisor.